U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO11.ClH
Molecular Weight 579.9812
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXORUBICIN HYDROCHLORIDE

SMILES

C[C@@]1([H])[C@]([H])([C@]([H])(C[C@@]([H])(O1)O[C@@]2([H])C[C@@](Cc3c2c(c4c(C(=O)c5cccc(c5C4=O)OC)c3O)O)(C(=O)CO)O)N)O.Cl

InChI

InChIKey=MWWSFMDVAYGXBV-RUELKSSGSA-N
InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C27H29NO11
Molecular Weight 543.5203
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/dosage/doxorubicin.html

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

CNS Activity

Curator's Comment:: Doxorubicin did not have access to areas of the brain within the blood-brain barrier, passed from the blood into the nervous parenchyma in those areas of the brain located outside the blood-brain barrier in mice

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.67 µM [IC50]
Target ID: CHEMBL614517
200.0 nM [IC50]
24.68 µM [IC50]
0.074 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DOXIL

Approved Use

Indicated for: Ovarian cancer After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma

Launch Date

8.1647999E11
Primary
DOXIL

Approved Use

Indicated for: Ovarian cancer After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma

Launch Date

8.1647999E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2 μM
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7.4 μM × h
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
34.8 h
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
25%
DOXORUBICIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Other AEs: Mucositis, Chills...
Other AEs:
Mucositis (severe, 1 patient)
Chills (1 patient)
Pyrexia (1 patient)
Sources:
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
Other AEs: Sinus tachycardia, Neutropenia...
Other AEs:
Sinus tachycardia (1 patient)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (1 patient)
Mucositis (severe, 1 patient)
Sepsis (severe, 1 patient)
Sources:
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Disc. AE: Tissue injury...
Other AEs: Acute myeloid leukaemia, Myelodysplastic syndrome...
AEs leading to
discontinuation/dose reduction:
Tissue injury (severe)
Other AEs:
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelosuppression (severe)
Sources:
300 mg/m2 1 times / 3 weeks multiple, intravenous (total)
Dose: 300 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Other AEs: Cardiomyopathy...
AEs

AEs

AESignificanceDosePopulation
Chills 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Pyrexia 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Mucositis severe, 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Sinus tachycardia 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
Thrombocytopenia 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
Neutropenia grade 4, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
Mucositis severe, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
Sepsis severe, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
Acute myeloid leukaemia
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Myelodysplastic syndrome
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Myelosuppression severe
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Tissue injury severe
Disc. AE
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Cardiomyopathy
300 mg/m2 1 times / 3 weeks multiple, intravenous (total)
Dose: 300 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes [Km 5.2 uM]
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Myocardial injury induced by a single dose of adriamycin: an electron microscopic study.
1976 Sep-Oct
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
1999
Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
1999
Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine.
1999 Apr
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
1999 Apr 1
Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis.
1999 Apr-Jun
Doxorubicin-induced cardiomyopathy.
1999 Feb 25
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.
1999 Jul
Effect of allopurinol in the course of adriamycin induced nephropathy.
1999 Mar
Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.
1999 May
Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant.
1999 May
Primary desmoplastic small cell tumor of soft tissues and bone of the hand.
1999 Nov
Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.
1999 Nov-Dec
Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin.
1999 Sep
Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin.
2000 Apr
Doxorubicin-induced late cardiotoxicity: delayed impairment of Ca2+-handling mechanisms in the sarcoplasmic reticulum in the rat.
2000 Apr
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
2000 Dec 1
Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat.
2000 Jan
Influence of Adriamycin and paraquat on antioxidant enzyme expression in primary rat hepatocytes.
2000 Jul
Doxorubicin-induced cardiomyopathy.
2000 Jul
Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis.
2000 Jul 1
Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method.
2000 Nov-Dec
Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events.
2000 Oct
ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy.
2001
Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients.
2001 Jan
Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters.
2001 Jan
Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
2001 Jan 1
Characterization of adriamycin-induced G2 arrest and its abrogation by caffeine in FL-amnion cells with or without p53.
2001 Jan 1
Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2.
2001 Jan 1
Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells.
2001 Jan 26
Mycosis fungoides and pregnancy.
2001 Jan-Feb
Patents

Sample Use Guides

When used in combination with other chemotherapy drugs, the most commonly used dosage of doxorubicin is 40 to 60 mg/m2 IV every 21 to 28 days. Alternatively, 60 to 75 mg/m2 IV once every 21 days.
Route of Administration: Intravenous
Alkalinization of extracellular pH by urease (2 U/ml) and urea (> or = 2 mM) was found to enhance the antitumor efficacy of doxorubicin (50 uM)
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:17:43 UTC 2021
Edited
by admin
on Fri Jun 25 21:17:43 UTC 2021
Record UNII
82F2G7BL4E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXORUBICIN HYDROCHLORIDE
EMA EPAR   EP   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
IMX-110 COMPONENT DOXORUBICIN HYDROCHLORIDE
Common Name English
(8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE HYDROCHLORIDE
Common Name English
ADRIAMYCIN, HYDROCHLORIDE
Common Name English
DOXORUBICIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
DOXORUBICIN HYDROCHLORIDE [USP-RS]
Common Name English
DOXORUBICIN HYDROCHLORIDE [EMA EPAR]
Common Name English
CAELYX
Brand Name English
DOXORUBICIN HYDROCHLORIDE LIPOSOME [VANDF]
Common Name English
DOXORUBICINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
DOXORUBICIN HYDROCHLORIDE [MART.]
Common Name English
DOXIL
Brand Name English
DOXORUBICIN HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
DOXORUBICIN HYDROCHLORIDE [USP]
Common Name English
HYDROXYDAUNOMYCIN HYDROCHLORIDE
Common Name English
DOXORUBICIN HCL
Common Name English
DOXORUBICIN HYDROCHLORIDE [VANDF]
Common Name English
DOXORUBICIN HYDROCHLORIDE [WHO-IP]
Common Name English
ADRIAMYCIN
Brand Name English
DOXORUBICIN HYDROCHLORIDE LIPOSOME
VANDF  
Common Name English
ADRIABLASTINA CS
Common Name English
ADRIAMYCIN [IARC]
Common Name English
RUBEX
Brand Name English
LIPOSOMAL DOXORUBICIN HYDROCHLORIDE [WHO-DD]
Common Name English
5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYLACETYL)-1-METHOXY-, HYDROCHLORIDE (8S-CIS)-
Common Name English
DOXORUBICIN LIPOSOMAL COMPLEX OF THE HYDROCHLORIDE [MI]
Common Name English
DOXORUBICIN HYDROCHLORIDE [JAN]
Common Name English
DOXORUBICIN HYDROCHLORIDE [WHO-DD]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/10/833
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
NCI_THESAURUS C67502
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
EMA ASSESSMENT REPORTS CAELYX (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
EMA ASSESSMENT REPORTS CAELYX (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
EMA ASSESSMENT REPORTS MYOCET (AUTHORIZED: BREAST NEOLPLASMA)
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 229006
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 191704
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 210705
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 628318
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 311910
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
246-818-3
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
FDA UNII
82F2G7BL4E
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
MERCK INDEX
M4757
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY Merck Index
RXCUI
142433
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DOXORUBICIN HYDROCHLORIDE
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY Description: A red-orange, crystalline powder. Solubility: Soluble in water and methanol R; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Doxorubicin hydrochloride should be kept in a tightly closed container. Additional information: Doxorubicin hydrochloride is hygroscopic; it is poisonous: CAUTION: Doxorubicin hydrochloride must behandled with care, avoiding contact with the skin and inhalation of airborne particles. Definition. Doxorubicin hydrochloride contains not less than 97.0% and not more than 102.0% of C27H29NO11,HCl, calculatedwith reference to the anhydrous substance.
EVMPD
SUB06391MIG
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
CAS
25316-40-9
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
PUBCHEM
443939
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
ChEMBL
CHEMBL53463
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
NCI_THESAURUS
C1326
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
RXCUI
466523
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
ALTERNATIVE
EVMPD
SUB01827MIG
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
EVMPD
SUB126795
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
ALTERNATIVE
DRUG BANK
DBSALT000060
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
USP_CATALOG
1225703
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY USP-RS
EPA CompTox
25316-40-9
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY